Atrial septal defect percutaneous closure

Jump to navigation Jump to search

Atrial Septal Defect Microchapters


Patient Information




Ostium Secundum Atrial Septal Defect
Ostium Primum Atrial Septal Defect
Sinus Venosus Atrial Septal Defect
Coronary Sinus
Patent Foramen Ovale
Common or Single Atrium


Epidemiology and Demographics

Risk Factors

Natural History and Prognosis



History and Symptoms

Physical Examination


Chest X Ray




Transesophageal Echocardiography
Transthoracic Echocardiography
Contrast Echocardiography

Transcranial Doppler Ultrasound

Cardiac Catheterization

Exercise Testing

ACC/AHA Guidelines for Evaluation of Unoperated Patients


Medical Therapy


Indications for Surgical Repair
Surgical Closure
Minimally Invasive Repair

Robotic ASD Repair
Percutaneous Closure
Post-Surgical Follow Up

Special Scenarios

Diving and Decompression Sickness
Paradoxical Emboli
Pulmonary Hypertension
Eisenmenger's Syndrome
Atmospheric Pressure

Case Studies

Case #1

Atrial septal defect percutaneous closure On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Atrial septal defect percutaneous closure

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Atrial septal defect percutaneous closure

CDC on Atrial septal defect percutaneous closure

Atrial septal defect percutaneous closure in the news

Blogs on Atrial septal defect percutaneous closure

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Atrial septal defect percutaneous closure

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2]; Cafer Zorkun, M.D., Ph.D. [3] Assistant Editor(s)-In-Chief: Kristin Feeney, B.S. [4]; Ahmed Zaghw, M.D. [5]


Percutaneous device closure is commonly performed to close an ostium secundum type of atrial septal defect and patent foramen ovales. It is still not FDA approved for closure of other forms of atrial septal defects such as primum, sinus venosus and coronary sinus. With proper patient selection at experienced centers, it has been found to be as successful, safe and effective as surgical closure. Additionally, it has been associated with fewer complications and a reduced length of stay compared to surgical closure [1].

Percutanous Closure

Mechanisms of Benefit

In percutaneous closure of atrial septal defects a self-expandable round disc is placed around the defect that prevents the left-to-right shunting of blood across the lesion. The mechanical prevention of this shunting helps improve the forward circulation in the heart, prevents shunting of blood, and prevents mixing of well exygenated blood with poorly oxygenated blood (shunting). It is associated with excellent results, particularly among those patients who have not developed irreversible pulmonary artery disease (Eisenmenger's syndrome).


The percutaneous closure of atrial septal defects is currently indicated only for children with secundum ASDs less than 30 mm in diameter as bigger defect is closed by surgery [2]

Percutaneous closure avoids cardiopulmonary bypass, thoracotomy, and atriotomy, and is associated with excellent outcomes.


It should not be used in patients with primum, sinus venosus and coronary sinus type of atrial septal defects. Surgical closure of ostium secundum atrial septal defect can be done when a concomitant tricuspid valve repair is considered or when the anatomy of the defect doesn't favor a percutaneous device.

Type of Occluders

The Amplatzer septal occluder (ASO) is currently the most widely used device because it is easy to implant and has high success rates. It first came to be used for human subjects in 1995. However, the device is still not approved for usage in percutaneous closure of primum,sinus venosus and coronary sinus type of atrial septal defects. It allows closure of large cavities, is easy to implant, and boasts high success rates. As an instrument, the Ampltazer septal occluder consists of two self-expandable round discs connected to each other with a 4-mm waist, made up of 0.004-0.005 nitinol wire mesh filled with dacron fabric. The prevalence of residual defect is low. The Food and Drug Administration has authorized the following percutaenous transcatheters for usage:[3].

  • Amplatzer septal occluder
  • CardioSEAL
  • HELEX septal occluder
  • Sideris patch

The following devices are still under investigation:

  • Buttoned device[4][5]
  • Angel wings[6]
  • Atrial septal defect occlusion system[7]


Percutaneous Repair

Percutaneous device closure of atrial septal defect, is currently approved only for secundum defects. Prior to the procedure, the patient is started on antiplatelet therapy for 6 months to prevent thrombus formation. Transesophageal echocardiography along with stop-flow technique is used for determining the device size, position and deployment.

Pre-Surgical Considerations

  1. Prior to undergoing percutaneous closure, eligible atrial septal defect patients must undergo pharmacologic preparation therapy.
  2. Most therapy regimens include antiplatelet drugs such as aspirin or clopidogrel for a minimum of six months to protect patients against thrombus formation.
  3. Secundum defects are assessed via echocardiographic monitoring to determine the anatomic viability of percutaneous closure.
  4. The ideal secundum defect is less than 30mm in diameter with an accompanying rim of tissue around the defect of at least 5mm.
  5. The rim of tissue serves to prevent impingement upon the superior vena cava (SVC), inferior vena cava (IVC), as well as the tricuspid or mitral valves.[8]

Steps During Percutaneous Closure

The salient feature of the percutaneous closure are-

  1. Device is placed via femoral vein.
  2. Best results are for centrally located secundum defects.
  3. Static diameter of the defect is assessed by using transesophageal echocardiography.
  4. Transesophageal echocardiography used for determining the device size, position, and deployment.
  5. A stop-flow technique is used to select the proper diameter of the device.
  6. In the stop flow technique, the sizing balloon is inflated until no flow is visible through the defect using transesophageal echocardiography.
  7. The margins of the defect must be ≤5 mm to accommodate the edges of the device.


Benefits of Percutaneous Closure

The percutaneous closure of ostium secundum is the method of choice in many centers.[9][10] The benefits that can be associated with the closure are as follow:

Disease Related Benefits

  • Fewer complications compared to surgical closure
  • Reduced need for blood transfusions
  • Symptomatic improvement
  • Regression of positive airway pressure
  • Positive changes in right ventricle performance
  • Improved functional capacity[11]
    • Left atrial volume index
    • Left ventricular myocardial performance index
    • Right ventricular myocardial performance index
    • Peak oxygen uptake

Other Benefits

  • Less invasive no need for cardiopulmonary bypass
  • Successful implantation rates of more than 96%
  • Established practice (done in most hospital these days)
  • Cost-effective
  • Shorter hospital stays


The frequency of complications with percutaneous closure is low, manifesting in under 9% of all cases. With experienced, skilled clinicians, the rate of complication may be as low as 1%.[12] Complications associated with percutaneous closure include:

Device Related

  • Device embolization
  • Malposition of the device
  • Device erosion

Medical Complications


The prognosis of percutaneous repair of atrial septal defect is generally good. However, the prognosis varies and depends on some factors like age at surgery, size of defect, amount of blood shunting and other associated co-morbidities at the time of repair. Some complications like pulmonary hypertension, Eisenmenger’s syndrome, right sided heart failure, arrhythmias (atrial fibrillation, atrial flutter) and stroke can occur after the repair. However, these are common in older patients(>40years) compared to younger patients.

Supportive Trial Data

Trials Comparing Percutaneous versus Surgical Closure

1) In a multicenter, non-randomized study performed in 29 pediatric cardiology centers, the patients were allotted to either the percutaneous closure or the surgical closure group depending on their preference. The success rate of the surgery was similar in the percutaneous closure and the surgical closure. However, the complication rates were more in the surgical groups (24%) compared to the percutaneous groups (7.2%). Also, the mean hospital stay was 3 days in surgical group compared to 1 day in the percutaneous device group. Additionally, surgical closure required sternotomy and cardiopulmonary bypass. With appropriate patient selection, device closure could be very successful. Also, it is safe and effective compared to other modalities.[1]

2) A study done on 45 subjects (15 with percutaneous closure, 15 with surgical correction and 15 control) to evaluate the left and right atrial function after transcatheter atrial septal defect closure compared with surgically treated ASD, using strain (epsilon) and epsilon rate imaging (SR) techniques, found that in the surgical corrected groups the peak systolic epsilon and SR values were significantly reduced compared to device and control group. Thus, it could be concluded that percutaneous closure helps in conserving both the atrial regional myocardial properties. [13]

Trials Testing the Efficacy and Safety of Device Closure

In a study done on 236 patients with ostium secundum (ASD), to evaluate the safety and efficacy of transcatheter closure with the amplatzer septal occluder, the device was found to be very efficient. It causes atrial septal defect closure in 84.7% of the treated patient population. During a median follow up of 2.3 years complete closure was documented in 94%, with a residual shunt only in 12 patients. Two of the treated patients were reported to have procedure related complications like retroperitoneal bleeding and air embolism.[14]


  1. 1.0 1.1 Du ZD, Hijazi ZM, Kleinman CS, Silverman NH, Larntz K, Amplatzer Investigators (2002). "Comparison between transcatheter and surgical closure of secundum atrial septal defect in children and adults: results of a multicenter nonrandomized trial". J Am Coll Cardiol. 39 (11): 1836–44. PMID 12039500.
  2. 2.0 2.1 Cao, Q.; Radtke, W.; Berger, F.; Zhu, W.; Hijazi, ZM. (2000). "Transcatheter closure of multiple atrial septal defects. Initial results and value of two- and three-dimensional transoesophageal echocardiography". Eur Heart J. 21 (11): 941–7. doi:10.1053/euhj.1999.1909. PMID 10806019. Unknown parameter |month= ignored (help)
  3. Schwetz BA (2002). "From the Food and Drug Administration". JAMA. 287 (5): 578. PMID 11829678.
  4. Zamora, R.; Rao, PS.; Lloyd, TR.; Beekman, RH.; Sideris, EB. (1998). "Intermediate-term results of Phase I Food and Drug Administration Trials of buttoned device occlusion of secundum atrial septal defects". J Am Coll Cardiol. 31 (3): 674–6. PMID 9502652. Unknown parameter |month= ignored (help)
  5. Aeschbacher, BC.; Chatterjee, T.; Meier, B. (2000). "Transesophageal echocardiography to evaluate success of transcatheter closure of large secundum atrial septal defects in adults using the buttoned device". Mayo Clin Proc. 75 (9): 913–20. doi:10.4065/75.9.913. PMID 10994827. Unknown parameter |month= ignored (help)
  6. Rickers, C.; Hamm, C.; Stern, H.; Hofmann, T.; Franzen, O.; Schräder, R.; Sievert, H.; Schranz, D.; Michel-Behnke, I. (1998). "Percutaneous closure of secundum atrial septal defect with a new self centering device (angel wings)". Heart. 80 (5): 517–21. PMID 9930056. Unknown parameter |month= ignored (help)
  7. Sievert, H.; Babic, UU.; Hausdorf, G.; Schneider, M.; Höpp, HW.; Pfeiffer, D.; Pfisterer, M.; Friedli, B.; Urban, P. (1998). "Transcatheter closure of atrial septal defect and patent foramen ovale with ASDOS device (a multi-institutional European trial)". Am J Cardiol. 82 (11): 1405–13. PMID 9856928. Unknown parameter |month= ignored (help)
  8. Ferreira SM, Ho SY, Anderson RH (1992). "Morphological study of defects of the atrial septum within the oval fossa: implications for transcatheter closure of left-to-right shunt". Br Heart J. 67 (4): 316–20. PMC 1024841. PMID 1389707.
  9. Bjørnstad P (2006). "Is interventional closure the current treatment of choice for selected patients with deficient atrial septation?". Cardiol Young. 16 (1): 3–10. PMID 16454871.
  10. Dhillon R, Thanopoulos B, Tsaousis G, Triposkiadis F, Kyriakidis M, Redington A (1999). "Transcatheter closure of atrial septal defects in adults with the Amplatzer septal occluder". Heart. 82 (5): 559–62. PMC 1760778. PMID 10525508.
  11. Salehian O, Horlick E, Schwerzmann M, Haberer K, McLaughlin P, Siu SC; et al. (2005). "Improvements in cardiac form and function after transcatheter closure of secundum atrial septal defects". J Am Coll Cardiol. 45 (4): 499–504. doi:10.1016/j.jacc.2004.10.052. PMID 15708694.
  12. Chessa M, Carminati M, Butera G, Bini RM, Drago M, Rosti L; et al. (2002). "Early and late complications associated with transcatheter occlusion of secundum atrial septal defect". J Am Coll Cardiol. 39 (6): 1061–5. PMID 11897451.
  13. Di Salvo G, Drago M, Pacileo G, Rea A, Carrozza M, Santoro G; et al. (2005). "Atrial function after surgical and percutaneous closure of atrial septal defect: a strain rate imaging study". J Am Soc Echocardiogr. 18 (9): 930–3. doi:10.1016/j.echo.2005.01.029. PMID 16153516.
  14. Fischer G, Stieh J, Uebing A, Hoffmann U, Morf G, Kramer HH (2003). "Experience with transcatheter closure of secundum atrial septal defects using the Amplatzer septal occluder: a single centre study in 236 consecutive patients". Heart. 89 (2): 199–204. PMC 1767528. PMID 12527678.

Template:WH Template:WS CME Category::Cardiology